#ExpertAnswers: Henry Holzgrefe and Belal Mohamed on Arrhythmia Detection
Airdate: Thursday, March 10, 2016 Season: 3 Episode: 1
Guests: Belal A. Mohamed, Henry Holzgrefe
This episode of #ExpertAnswers features Henry Holzgrefe, Safety Pharmacology Consultant, Charles River Laboratories and Belal A. Mohamed, MD, Clinic of Cardiology and Pneumology, Georg-August-Universität Göttingen. They are here to discuss arrhythmia detection and improving data analysis in the preclinical research setting.
For more information or to watch the webinar, click here.
Associated Webinar: Don’t Miss a Beat: Arrhythmia Detection for Preclinical ECG Research
Similar Podcasts
#ExpertAnswers: Artur Federowoski on Cardiovascular Dysautonomia in Post-COVID-19
Artur Federowski explains CV dysautonomia as a specific sequalae of acute COVID-19 and guides the audience in the diagnostic work-up of PASC patients with suspected cardiovascular complications.
#ExpertAnswers: Phil Griffiths on Telemetry Studies
Phil Griffiths draws from his experience as a telemetry user to discuss some important considerations for designing telemetry studies.
#ExpertAnswers: Cole McLarty, Nick Glover, and Tim Hacker on Pressure-Volume Loops
Cole McLarty, Nick Glover and Dr. Timothy Hacker focus on Pressure-Volume Loop collection and data analysis for cardiovascular research.
Related Content
Peripheral and Cerebral Vascular Responses Following High-Intensity Interval Exercise
Dr. Bert Bond and Max Weston will present an overview on their study investigating the effects high-intensity interval exercise has on cerebrovascular health.
Cardiovascular Autonomic Dysfunction in the Post-COVID Landscape: Detection and Management
Artur Fedorowski, MD, PhD, describes cardiovascular dysautonomia in COVID-19 and the diagnostics behind detecting Long COVID or Post-acute Sequalae of COVID-19.
APS Physiology in Disease Modeling and Drug Development Roundtable
Key opinion leaders in cardiovascular physiology and bioengineering discuss best practices and challenges when modeling cardiomyopathies and other cardiovascular diseases using stem cells, engineered tissues and other novel platforms.